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Introduction: CDKN2A (p16) inactivation is common in lung can-
cer and occurs via homozygous deletions, methylation of promoter 
region, or point mutations. Although p16 promoter methylation has 
been linked to KRAS mutation and smoking, the associations between 
p16 inactivation mechanisms and other common genetic mutations 
and smoking status are still controversial or unknown.
Methods: We determined all three p16 inactivation mechanisms 
with the use of multiple methodologies for genomic status, methyla-
tion, RNA, and protein expression, and correlated them with EGFR, 
KRAS, STK11 mutations and smoking status in 40 cell lines and 45 
tumor samples of primary non–small-cell lung carcinoma. We also 
performed meta-analyses to investigate the impact of smoke expo-
sure on p16 inactivation.
Results: p16 inactivation was the major mechanism of RB pathway 
perturbation in non–small-cell lung carcinoma, with homozygous 
deletion being the most frequent method, followed by methylation 
and the rarer point mutations. Inactivating mechanisms were tightly 
correlated with loss of mRNA and protein expression. p16 inacti-
vation occurred at comparable frequencies regardless of mutational 
status of EGFR, KRAS, and STK11, however, the major inactiva-
tion mechanism of p16 varied. p16 methylation was linked to KRAS 
mutation but was mutually exclusive with EGFR mutation. Cell lines 
and tumor samples demonstrated similar results. Our meta-analy-
ses confirmed a modest positive association between p16 promoter 
methylation and smoking.
Conclusion: Our results confirm that all the inactivation mechanisms 
are truly associated with loss of gene product and identify specific 
associations between p16 inactivation mechanisms and other genetic 
changes and smoking status.
Key Words: p16, CDKN2A, Inactivation, Homozygous deletion, 
Methylation, Lung cancer, Adenocarcinoma, Meta-analysis.
(J Thorac Oncol. 2013;8: 1378–1388)
Lung cancer is the second most common type of cancer and the leading cause of cancer-related deaths in both men and 
women in the United States. According to the cancer statis-
tics review from the Surveillance, Epidemiology, and End 
Results program of the U.S. National Cancer Institute (NCI), 
the age-adjusted death rate was 51.6 per 100,000 in both men 
and women per year during 2004–2008.1 A total of 226,160 
new cases of lung cancer and 160,340 deaths from lung cancer 
were projected to occur in the United States in 2012.2
There are two major types of lung cancer, non–small-
cell lung carcinoma (NSCLC) and small-cell lung carcinoma. 
NSCLC can be further divided into three main subtypes: 
large-cell lung carcinoma, squamous-cell lung carcinoma, 
and adenocarcinoma. Adenocarcinoma accounts for approxi-
mately 40% of lung cancers and is the most common type of 
lung cancer in the United States.3,4
Most cases of lung cancer, including adenocarcinoma, 
are caused by tobacco smoking. However, approximately 25% 
of lung cancer cases worldwide and about 15% of the cases in 
the United States are not attributable to smoking.5,6 The most 
common type of lung cancer among never smokers is adeno-
carcinoma, and it is found to be more prevalent among East 
Asians and women. Despite advances in oncology, the 5-year 
survival rate of patients with lung adenocarcinoma has not 
changed significantly over the past three decades. The NCI 
Surveillance, Epidemiology, and End Results program showed 
that about 84% of lung adenocarcinoma patients die within 5 
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years of diagnosis.1 We believe lung cancer prognosis can be 
improved by a combination of early detection7 with advances 
in biology and the subsequent implementation of effective tar-
geted therapies such as those directed against EGFR muta-
tions and ALK translocations.8,9
Studies have shown that patients with lung adeno-
carcinoma often have genetic mutations in EGFR, KRAS, 
STK11 (also known as LKB1), TP53 (also known as p53), 
and CDKN2A (also known as p16 or INK4a).10–14 Several new 
potential targets for therapeutic approaches have also been 
identified recently.15,16 A study of these mutations may eventu-
ally lead to novel therapeutic applications.
One of the most common genetic alterations in many 
forms of cancer including lung adenocarcinoma is inactiva-
tion of p16. p16 is located at chromosome region 9p21 and is 
encoded by the CDKN2A gene. In addition to p16, CDKN2A 
encodes a completely unrelated tumor suppressor protein, ARF, 
which interacts with TP53. The simple tandem arrangement is 
complicated by the presence of an additional exon 1β, which is 
transcribed from its own promoter. The resulting RNA incor-
porates exons 2 and 3 but specifies a distinct protein because 
the exons are translated by an alternative reading frame. Thus, 
although exons 2 and 3 are shared by the two mRNAs, they 
encode different protein products, p16 and ARF.17
p16 is a tumor suppressor, functions as an inhibitor 
of CDK4 and CDK6, the D-type cyclin-dependent kinases 
that initiate the phosphorylation of the retinoblastoma tumor 
suppressor protein RB, and induces cell-cycle arrest.18 Both 
alleles must be inactivated before its function is eliminated. 
Three mechanisms have been implicated in its inactivation: 
homozygous deletion (HD), hypermethylation in the pro-
moter CpG island (methylation), and point mutation. It has 
been reported that p16 is frequently inactivated by HD or 
promoter hypermethylation, and rarely by point mutation in 
primary NSCLC.12,19 Studies demonstrated that the frequency 
of p16 methylation is significantly higher in lung adenocarci-
noma with KRAS mutation, however, the associations between 
p16 inactivation mechanisms and other common genetic 
mutations in lung adenocarcinoma such as EGFR and STK11 
remain controversial or have never been explored.20 Smoking 
has been reported to be associated with p16 methylation and 
p16 HD was found to be associated with never smokers in 
some studies, but these findings are inconsistent.12,19–21
Despite the large number of reports, many of these 
associations remain controversial, in part because the major-
ity of the reports (1) do not examine all the mechanisms of 
inactivation, and (2) do not demonstrate that the inactivating 
mechanism(s) studied were truly associated with inactivation 
of the gene. Therefore, the aims of the present study were to: 
(1) examine all the three described inactivation mechanisms 
of p16 in lung cancer cell lines and tumor samples; (2) demon-
strate that our methods of detecting inactivation are truly asso-
ciated with inactivation; (3) correlate the data with data on 
tobacco exposure; and (4) correlate inactivation mechanisms 
with molecular features. Because one of our major interests 
was correlation with tobacco exposure, we aimed to study suf-
ficient numbers of cancers arising in never smokers. Thus, with 
a few exceptions, we limited our study to adenocarcinoma as 
they are by far the most common form of lung cancer arising 
in never smokers.
MATERIALS AND METHODS
Cell Culture
Forty NSCLC cell lines were used in the study. Thirty-
six of them were lung adenocarcinomas, one was large-cell 
carcinoma, one was adenosquamous carcinoma, and two 
were unspecified NSCLC cell lines. Data for the cell lines 
have been reported in multiple previous studies.22–24 In this 
study, light smokers were defined as patients with less than 
15 pack-year history. Heavy smokers were defined as those 
who had a smoking history of 15 pack-years or more. Refer 
to Supplementary Table 1 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A465) for further information.
Tumor Samples
Forty-five tumor samples were included in this study 
and all of them were obtained from patients with primary 
lung adenocarcinoma. Institutional review board approval and 
informed consents were obtained from the patients for molec-
ular analysis of the samples. Among the 45 tumor samples, 29 
of them were obtained from smokers, either current or former 
smokers, and 16 of them were from never smokers. Further 
details about smoking histories were not available. Refer to 
Supplementary Table 2 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A465) for further information.
DNA, RNA Extraction, and cDNA Synthesis
Genomic DNA was obtained from cell lines and tumor 
samples by standard phenol–chloroform extraction or by using 
the DNeasy Tissue Kit (QIAGEN, Alameda, CA). Total RNA 
was extracted from cell lines using the RNeasy Plus Mini Kit 
(QIAGEN). The cDNA was prepared by reverse transcription 
of RNA using High-Capacity cDNA Reverse Transcription 
Kits (Applied Biosystems, Foster City, CA) according to the 
manufacturer’s protocol.
p16 Inactivation Methodology
Because of the multiple methods used to determine and 
confirm inactivation, and their applications to tumors and cell 
lines, these methods are summarized in Supplementary Table 
3 (Supplemental Digital Content 1, http://links.lww.com/JTO/
A465) and detailed below.
Homozygous Deletions
HDs of p16 in cell lines were detected using SYBR 
green (Bio-Rad Laboratories, Inc., Irvine, CA) real-time 
quantitative polymerase chain reaction (qPCR) and single-
nucleotide polymorphism (SNP) which will be discussed 
later in the article. The sequences of the primers used were 
forward: 5′-GTGAAGCCATTGCGAGAACT-3′ and reverse: 
5′-TTCTTTCAATCGGGGATGTC-3′, and both primers 
recognize sequences located in intron 2. The reactions were 
performed in a Bio-Rad DNA Engine Thermal Cycler (Bio-
Rad Laboratories, Inc.). The thermal cycling conditions were 
set to 2 minutes at 50°C, 10 minutes at 95°C, followed by 
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40 cycles of 15 seconds at 95°C alternating with 1 minute at 
60°C. Standard curves for the copy numbers were generated 
using human diploid genomic DNA as a reference. DNA copy 
number ratios were calculated as the average copy number of 
the target locus divided by the average copy number of line 
1, which is used as the reference locus, and then normalized 
against the human genomic DNA. HD was defined as copy 
number equal to or less than 0.001 and the copy number of 
human genomic DNA was set at 2.
HDs of p16 in tumor samples were identified using 
SNP arrays. The Genome-Wide Human SNP Array 6.0 plat-
form (Affymetrix Inc., Santa Clara, CA) was used to pro-
file each tumor. Copy number profiles were generated with 
Partek Genomics Suite (PGS) software, using the Paired Copy 
Number Analysis workflow. In this analysis, matched nonma-
lignant lung tissue is used as a copy number baseline for defin-
ing copy number alterations in each tumor. Regions of copy 
number gain and loss were statistically detected using PGS’s 
genomic segmentation algorithm with the following param-
eters: signal to noise ratio more than 0.3, minimum number of 
50 probes per segment, and p value thresholds of 10−7 for the 
statistical differences between (1) signal intensities of adjacent 
segments, and (2) tumor and nonmalignant lung DNA. Copy 
numbers were estimated by the PGS genomic segmentation 
algorithm, and HD was defined as a copy number less than 
1. p16 was mapped to the genomic regions detected using the 
hg18 genome coordinates of March 2006 from the University 
of California Santa Cruz (UCSC) Genome Browser.
Methylation Analysis
The methylation status of CpG islands in the p16 gene 
promoter was determined by methylation-specific qPCR 
(MSP) using real-time qPCR and fluorescent Taqman chem-
istry. The probes used to assess methylation were located in 
exon 1, and their selection was based on the results of qPCR 
in our previous study.25 Bisulfite conversion of DNA was per-
formed using the EZ DNA Methylation Gold kit by Zymo 
Research (Irvine, CA). All other materials and methods for 
MSP were as described in prior studies.21,25
The methylation status of p16 in cell lines was con-
firmed using the Infinium HumanMethylation 450K 
BeadChip by Illumina (San Diego, CA). Because the Illumina 
HumanMethylation 450K BeadChip data was not available 
for our tumor samples, we downloaded the data for squa-
mous cell and adenocarcinoma lung cancer from The Cancer 
Genome Atlas (TCGA) data portal (https://tcga-data.nci.nih.
gov/tcga). The β values of all samples were merged into a 
data matrix. Tumor samples and nonmalignant samples were 
identified from the sample bar code according to the TCGA 
documentation. A t test was then applied to each methylation 
probe to search for statistically significant differential meth-
ylation between tumor samples and nonmalignant samples. 
Methlyation was defined as tumor samples with β scores of 
0.3 or higher than the mean values for nonmalignant tissues.
Point Mutation Analysis
Sequencing of p16 was performed in all cell lines 
and tumor samples to detect point mutations. Sequencing 
of both genomic DNA and cDNA were performed depen-
dent on material availability, and all the reactions were 
performed using the Applied Biosystem GeneAmp PCR 
System 9700 instrument. For DNA sequencing, exon 1 
was amplified by PCR using the following primers: for-
ward: 5′-GAAGAAAGAGGAGGGGCT-3′ and reverse: 
5′-GCGCTACCTGATTCCAATTC-3′. PCR was performed 
for 42 cycles consisting of denaturation at 94°C for 1 min-
ute, annealing at 57°C for 1 minute, and extension at 72°C 
for 2 minutes. Exon 2 was amplified using the following 
primers: forward: 5′-AGCTTCCTTTCCGTCATGC-3′ 
and reverse: 5′-GGAAGCTCTCAGGGTACAAATTC-3′. 
PCR was performed for 42 cycles consisting of dena-
turation at 94°C for 1 minute, annealing at 48°C for 1 
minute, and extension at 72°C for 2 minutes. For ampli-
fication of exon 3, the following primers were used: for-
ward: 5′-CCTGGCATTGTGAGCAACC-3′ and reverse: 
5′-GGTTCTGGCATTTGCTAGCAG-3′. PCR was per-
formed for 42 cycles consisting of denaturation at 94°C for 1 
minute, annealing at 55°C for 1 minute, and extension at 72°C 
for 2 minutes. For cDNA sequencing, the following primers 
were used: forward: 5′-CGGAGGAAGAAAGAGGAG-3′ 
and reverse: 5′-TTCTCAGAGCCTCTCTGGT-3′. PCR was 
performed for 44 cycles consisting of denaturation at 94°C 
for 1 minute, annealing at 50°C for 90 seconds, and exten-
sion at 72°C for 2 minutes.
Exome sequencing was performed on an Illumina 
GAIIx platform using standard procedures. Postsequence data 
was processed with Illumina Pipeline software v 1.7.
Expression Analysis
Taqman gene expression assay for p16 was used to 
quantitatively detect p16 mRNA levels according to the manu-
facturer’s protocol (Applied Biosystems).
RNA-seq was also used to measure p16 transcript expres-
sion levels. One microgram of total RNA per sample was poly-
A tail purified, fragmented, and adapter ligated using Illumina 
TruSeq RNA sample prep kit version 2, following the instruc-
tions of manufacturers. Samples were multiplexed four to a lane 
on the Illumina HiSeq 2000 using the Single Read version 3 
flowcell and underwent a 100 base pair single-end run using 
TruSeq version 3 SBS kits. Sequencing was performed at the 
Southern California Genotyping Consortium, University of 
California, Los Angeles, California. Sequence data was read 
using Illumina OBC (off-line base caller) software, was trimmed 
to remove adapter reads, and aligned to the National Center for 
Biotechnology Information (NCBI). GrCh37 (hg19) transcrip-
tome using CLCbio Genomics Workbench version 5.1. Reads 
with more than three mismatches to the reference genome (poor 
alignment) or more than 10 identical copies (PCR bias) were 
discarded. Coverage was determined by read density over the 
gene body and used to estimate expression levels.
Protein expression of p16 was assessed by mass spectro-
metric (MS) analysis. The collection of whole cell extracts was 
performed as described in a previous study.26 Protein diges-
tion and identification by liquid chromatography-MS/MS 
were performed as described previously.26 Three International 
Protein Indexes (IPIs) were identified for CDKN2A in which 
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IPI00001560 and IPI00651662 correspond to p16 whereas 
IPI00478390 corresponds to ARF.
Mutation Status of EGFR, KRAS, STK11,  
TP53, and RB
The 40 cell lines and 45 tumor samples in our study were 
examined for mutations in exons 18 to 21 of the EGFR gene 
and exons 1 and 2 of the KRAS gene by genomic PCR and direct 
sequencing as described in our previous studies.27–29 Mutations 
in exons 1 to 9 of the STK11 gene were detected by cDNA 
sequencing in both cell lines and tumors. The following primers 
were used: forward: 5′-GAAGGGAAGTCGGAACACAA-3′ 
and reverse: 5′-CCCTGGCTATGCAGGTACTC-3′; forward: 
5′-ATGGAGTACTGCGTGTGTGG-3′ and reverse: 5′-CAG 
CCGGAGGATGTTTCTT-3′; forward: 5′-GTTTGAGAACAT 
CGGG AAGG-3′ and reverse: 5′-AACCGGCAGGAAGAC 
TGAG-3′. Mutations in exons 1 to 11 of the p53 gene were detected 
by cDNA sequencing only in cell lines. The following prim-
ers were used: forward: 5′-GCTTTCCACGACGGTGAC-3′ 
and reverse: 5′-TGACTGCTTGTAGAT GGCCA-3′; forward: 
5′-GTCTGGGCTTCTTGCATTCT-3′ and reverse: 5′-TCTTG 
CGGA GATTCTCTTCC-3′; forward: 5′-CCTCACCATCATC 
ACACTGG-3′ and reverse: 5′-TTCT GACGCACACCTT 
GC-3′. The mutation data for RB in 40 NSCLC cell lines were 
obtained from Sanger Institute Catalog Of Somatic Mutations 
In Cancer.
Copy Number Analysis of CCND1,  
CDK4, and CDK6
The copy numbers of CCND1, CDK4, and CDK6 in 
40 cell lines were detected using SYBR green real-time 
PCR (qPCR). The sequences of the primers used for CCND1 
were forward: 5′-GCGGAGGAGAACAAACAGAT-3′ and 
reverse: 5′-ACCCAGGTGGAGAGCAAGA-3′; for CDK4, 
forward: 5′-TTGTTGCTGCAGGCTCATAC-3′ and reverse: 
5′-ATAGGCACCGACACCAATTT-3′; for CDK6, for-
ward: 5′-ATTCAAAATCTGCCCAACCA-3′ and reverse: 
5′-GCAGACGAGCTTGACATCAG-3′. The detailed method 
was described in the section on HD.
Statistical Analysis
Frequencies of all three p16 inactivation mechanisms in 
each mutational group (EGFR, KRAS, and STK11 mutation), 
and smoking group were compared using Fisher’s exact test. 
Some of these genetic mutations are known to be associated 
with each other, smoking status, sex, and ethnicity. To pre-
vent the potential confounding effect of multiple variables, a 
multivariate logistic regression model was used to analyze the 
association of specific genetic mutations or smoking status 
with the various mechanisms of p16 inactivation. Results with 
p value less than 0.05 were regarded as statistically significant.
Meta-Analysis
Literature published from 2001 to May 2012 in PubMed 
database were screened by using key words “p16 or CDKN2A 
or INK4A” and “smoking or tobacco,” and “promoter meth-
ylation” or “HD” or “mutation” or “inactivation” to determine 
the impact of smoking. Key words “never smoker” or “never 
smoke,” or “never smoking” were used instead of “smok-
ing” or “tobacco” in the meta-analysis for never smokers. 
Only articles providing raw data and published in English 
were selected. The meta-analyses were performed using R 
(www.r-project.org) with the Rmeta package. A Woolf’s test 
was performed to identify heterogeneity among publications. 
The random-effects model was used for heterogeneous stud-
ies whereas the fixed-effects model was applied if the studies 
were homogeneous.30 To prevent one of the studies from dom-
inating the results by contributing a larger number of samples 
or a big effect size, we adopted the leave-one-out strategy by 
removing data from each study one at a time and detected how 
the overall odds ratio (OR) had changed. The overall OR was 
found to remain significantly greater than one no matter which 
study was removed in both meta-analyses, hence none of the 
selected studies dominated the result.
RESULTS
Multiple Methodologies for the Detection  
of p16 Inactivation
p16 can be inactivated by HD, hypermethylation of pro-
moter CpG islands, or point mutations. In this study, we inves-
tigated the inactivation mechanisms of p16 in 40 NSCLC cell 
lines and 45 NSCLC tumor samples. As shown in Table 1, the 
frequency of p16 inactivation was higher in cell lines (75%) 
compared with that of tumor samples (38%), and this has been 
observed in previous studies.14 Despite the higher frequency of 
inactivation in cell lines, no evidence of difference in the pro-
portions of p16 inactivation mechanisms was found between 
cell lines and tumor samples. Hence, the results for tumors 
and cell lines are presented individually and were also com-
bined to increase the sample size for our analyses (Table 1).
HD was the most frequent mechanism of inactivation in 
both cell lines (53%) and tumors (59%), as detected by copy 
number changes (SNP arrays). Representative examples of 
TABLE 1.  Frequency and Mechanisms of p16 Inactivation
Frequency of p16 Inactivation 
(%)
Mechanisms of p16 Inactivation
HD (%) Methylation (%) Mutation(%)
Cell lines 30/40 (75) 16/30 (53) 10/30 (33) 4/30 (13)
Tumors 17/45 (38) 10/17 (59) 4/17 (24) 3/17 (18)
Combined 47/85 (55) 26/47 (55) 14/47 (30) 7/47 (15)
HD, homozygous deletion.
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HDs are shown in Figure 1. For cell lines, qPCR was used to 
confirm the results of the SNP arrays.
The methylation status of p16 was assessed by quan-
titative MSP analysis. p16 methylation was present in 30% 
(33% for cell lines and 24% for tumors) of samples with p16 
inactivation. We also confirmed these results of 38 cell lines 
(data were not available for cell lines PC-9 and DFCI032) 
by Illumina Infinium Human Methylation 450K BeadChip. 
Probe cg13601799 for detecting exon one of p16 (E1α) and 
probe cg03079681 located in exon one of p14ARF (E1β) 
were selected (Fig. 2A). Only cell lines with methylated 
p16 detected by MSP analysis showed high levels of meth-
ylation using probe cg13601799, and these cell lines are not 
methylated in p14ARF exon 1 (probe cg03079681; Fig. 2B). 
Among them, NCI-H969 showed partial methylation of p16 
as indicated by its β value. Of interest, there are some values 
for β scores in the cell lines carrying an HD of the CDKN2A 
locus. These probably result from deletions in the region, 
which are artifactually affecting the β value resulting from a 
comparison of the unmethylated and methylated probes. Thus 
the results do not reflect the correct methylation status of the 
cell lines. We also examined the methylation status of NSCLC 
cancers in the TCGA database (Fig. 2C). We found that p16 
methylation was more frequent in squamous cell carcinomas 
(36%) than in adenocarcinomas (17%), which is consistent 
with published reports.15
The p16 mutational status was determined by direct 
sequencing for cell lines and tumors. p16 mutations were 
present in 15% (13% for cell lines and 18% for tumors) of 
FIGURE 1.  HDs of p16 in lung adenocarcinoma tumors and cell lines. Affymetrix SNP six arrays were used to generate copy 
number profiles for lung adenocarcinoma cell lines and clinical lung tumors. Allele-specific copy numbers were derived using 
the allele-specific copy number workflow in PGS software. Copy number profiles for lung cancer cell lines were generated using 
a panel of 72 nondiseased HapMap individuals as a baseline whereas matched nonmalignant lung tissue was used as a reference 
for defining copy number changes in tumors. Arrows indicate region of the p16 gene. A, Focal HD of p16 in the lung adeno-
carcinoma cell line, NCI-H1944. B, Lung adenocarcinoma tumor illustrating neutral p16 copy number state. C, Focal HD of p16 
in a lung adenocarcinoma tumor. Both HDs in (A) and (C) occur in a background of single copy loss on chromosome 9p. Copy 
number states in regions of deletion do not drop right to zero because of to cancer cell heterogeneity, aneuploidy, and/or the 
presence of nonmalignant cells that contribute to array signals. Maximum (red) and minimum (blue) alleles are defined by copy 
number state. Each dot represents the smoothed copy number for 30 adjacent array probes. Copy number states (HD, single 
copy loss, or copy neutral) are indicated. Images were generated in PGS. Arrows indicate location of p16 gene at chromosome 
9p21.3. HD, homozygous deletion; PGS, Partek Genomics Suite.
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p16 inactivation. Additionally, the results were confirmed by 
next-generation sequencing in the cell lines.
In summary, the results obtained by different methods 
designed to measure the same type of inactivation (HD, meth-
ylation, or sequence mutation) were concordant with each 
other in every case.
Association between p16 Inactivation and  
Its mRNA and Protein Expression
As shown in Figure 3A (with details presented in 
Supplementary Table 4, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A465), the concordance between 
all the three inactivation mechanisms (HD, methylation, point 
mutations) and RNA and protein expression were excellent. 
With the exception of one partially methylated cell line (NCI-
H969), all HD and methylated cell lines showed absent RNA 
or protein expression. With the exception of PC-9, cell lines 
with point mutations expressed low or absent levels of mRNA 
and protein. Thus 28 of 30 cell lines (93%) demonstrating any 
method of inactivation lacked p16 expression. By contrast, 
nine of 10 (90%) of wild-type (WT) lines expressed varying 
levels of mRNA expression and eight of nine (89%) had pro-
tein expression.
For representative cell lines we confirmed our results 
using RNA-Seq data. We selected four NSCLC cell lines 
(NCI-H2228, NCI-H1975, NCI-H23, and NCI-H522) to rep-
resent the different statuses of p16 (HD, mutation, methyl-
ated, and WT, respectively), as illustrated in Figure 3B. Unlike 
ARF (E1β), which was detected in the other three cell lines 
except for the p16 HD cell line, p16 expression (E1α) was 
only detected in the p16 WT cell line. These data indicate that 
all three p16 inactivation mechanisms (HD, methylation, point 
mutation) affect p16 expression levels.
FIGURE 2.  Methylation of p16 promoter in lung cancers and cell lines. A, Schematic diagram of CDKN2A (p14ARF-p16INK4a) 
genomic locus. Colored boxes represent exons of p16INK4a or p14ARF. The coding regions are shown as green, whereas 
the noncoding regions shown as yellow. The locations of the CDKN2A MSP probe and corresponding Illumina Methylation 
450K BeadChip probes are indicated. B, The methylation status of p16 in the NSCLC cell lines by Illumina Methylation 450K 
BeadChip probes. The methylation β values from cell lines carrying a HD of the CDKN2A locus, DNA methylation of the CpG 
island in exon 1a (p16INK4a) (Meth), a point mutation in p16INK4a (Mut), or no detectable alteration of the locus (WT) are 
plotted. A value of 0 indicates nonmethylation of the locus; a value of 1 means complete methylation. C, The methylation status 
of p16 in lung cancers from TCGA data portal by Illumina Methylation 450K BeadChip probes. The methylation β values from 
LUSC or LUAD and nonmalignant lung tissues are plotted. Methlyation was defined as tumor samples with β scores of 0.3 or 
higher than the mean values for nonmalignant tissues. MSP, methylation-specific polymerase chain reaction; NSCLC, non–small-
cell lung carcinoma; TCGA, The Cancer Genome Atlas; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma;  
HD, homozygous deletion; WT, wild-type.
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P16 Inactivation in Lung Adenocarcinoma 
with Other Genetic Mutation
Because EGFR, KRAS, and STK11 are frequently 
mutated in lung adenocarcinomas,9,11 we investigated the 
association between mutational status of these genes and p16 
inactivation. Among the 40 cell lines, 10 were EGFR mutants, 
15 were KRAS mutants, and 15 were STK11 mutants. As pre-
viously reported, EGFR and KRAS mutations were mutually 
exclusive.28 Mutations of EGFR and STK11 were also found 
to be mutually exclusive in the 40 cell lines. KRAS and STK11 
mutations coexisted in seven cell lines. Of the 45 tumor sam-
ples, 14 had EGFR mutations, 21 had KRAS mutations, and 
20 had STK11 mutations. Again, the EGFR and KRAS muta-
tions were mutually exclusive. Six of the tumor samples had 
coexisting STK11 and EGFR mutations, whereas seven tumor 
samples had mutations in both STK11 and KRAS. The detailed 
information of mutational status of each sample is provided in 
Supplementary Tables 1 and 2 (Supplemental Digital Content 
1, http://links.lww.com/JTO/A465).
Overall p16 inactivation was detected with compa-
rable frequencies regardless of EGFR, KRAS, and STK11 
mutational status. Figure 4 and Supplementary Table 5 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A465) show a summarization of the data. Among all EGFR 
mutants, p16 was mostly inactivated by HD (42% combined 
from cell lines and tumor samples, 50% in cell lines, and 36% 
in tumor samples), and the remainder demonstrated p16 inac-
tivation by point mutation (13% combined, 20% in cell lines, 
and 7% in tumor samples). None of the EGFR-mutated cases 
demonstrated p16 promoter methylation, which has been 
identified as a common mechanism of p16 inactivation in lung 
adenocarcinomas in this as well as in a number of other stud-
ies.9,12,25 Our analysis revealed that EGFR mutations and p16 
methylation were mutually exclusive in all cases, although our 
sample size was modest. By contrast KRAS mutations were 
positively correlated with p16 methylation (for cell lines, 
p = 0.025; for tumors, p = 0.025; for combined, p = 0.003). 
We did not note any significant relationships between STK11 
or p53 (data not shown) mutations and mechanisms of p16 
inactivation.
Other variables including smoke exposure, sex, and 
ethnicity have been reported to be associated with specific 
mutations. For instance, EGFR mutation is more prevalent 
in women, Asians, and never smokers whereas KRAS and 
STK11 mutations were more often found in smokers. Given 
these known relationships, it is plausible that p16 inactivation 
FIGURE 3.  Expression analysis of the CDKN2A locus in NSCLC cell lines. A, Heatmap shows RNA and protein expression 
levels in cell lines carrying no detectable alteration of the CDKN2A locus (WT), DNA methylation of the CpG island in exon 1a 
(p16INK4a) (Meth), a point mutation in p16INK4a (Mut), or an HD of the locus. RNA expression was determined by qPCR. The 
relative mRNA levels of p16 were compared with that of nonmalignant immortalized HBECs. Protein expression was determined 
by mass spectrometry. *Indicates Rb mutants. B, RNA-Seq data for the CDKN2A locus for representative cell lines. The differ-
ent splice variants arising from the locus are indicated. Genome-wide coverage was similar for all four lines. Peaks detected are 
shown to scale. No signal was detected in the HD line (NCI-H2228), p14ARF mRNA, but not p16INK4a was detected in the 
Mut (NCI-H1975) or Meth (NCI-H23) lines; mRNA containing exon 1a (p16INK4a) was only detected in WT line (NCI-H522). 
HD, homozygous deletion; NSCLC, non–small-cell lung carcinoma; HD, homozygous deletion; HBECs, bronchial epithelial cells; 
WT, wild-type; qPCR, quantitative polymerase chain reaction.
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mechanisms may also be associated with specific clinical 
features in addition to the molecular features described 
above. To decipher the effects of multiple clinical and 
genetic variables, a multivariate logistic regression model 
was used to determine the associations between particular 
genetic mutation and p16 inactivation mechanisms. The 
results were consistent with our initial univariate analyses 
described above.
We also investigated genetic alterations of other com-
ponents of the pathway. Although 75% NSCLC cell lines 
contained p16 inactivation, only two of 40 (5%) had RB muta-
tions (Fig. 5 and Supplementary Table 6, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A465). We also analyzed 
the copy number changes of cyclin D1, CDK4, and CDK6 in 
these cell lines. Low-level gains were present in 20% to 25% 
of the lines (Fig. 5, Supplementary Table 6, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A465), whereas 
high-level amplifications were rare.
P16 Inactivation in Smokers and Never Smokers
We failed to find a relationship between smoking 
status and frequency or method of inactivation of the p16 
gene (Fig. 4, Supplementary Table 5, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A465). Because 
there are contradictory reports on the relationship of 
smoking status and p16 methylation, we performed meta-
analyses to investigate the relationship of smoking status 
and p16 methylation as well as with any mechanism of 
inactivation.11,12,19–21,30–49
Meta-Analysis of Smoke Exposure and p16  
Methylation
Promoter methylation of p16 is reportedly associated 
with smoking in some studies but not in others. To address 
these variable findings, we performed a meta-analysis in 
addition to analyzing our own data. A total of 23 studies con-
taining 1903 smokers and 982 nonsmokers, were selected as 
described in the Materials and Methods section. A Woolf’s 
test was performed to test for heterogeneity among the studies 
selected, and the results showed that the studies were hetero-
geneous (χ2 test = 39.29; df = 23; p = 0.018). A random-effects 
model was therefore applied and the overall OR from the 
meta-analysis was 1.99, which was significant (p < 0.05) with 
95% confidence interval between 1.48 and 2.72. Therefore, 
our meta-analysis based on the published literature confirmed 
a positive association between p16 promoter methylation and 
smoking (Fig. 6).
Meta-Analysis Smoke Exposure and Other p16  
Inactivation Mechanisms
Although the association between promoter methylation 
and smoking has been extensively studied, little has been done 
to explore the potential association between smoke exposure 
and other p16 inactivation mechanisms. We performed a sec-
ond meta-analysis to evaluate the association between smoke 
FIGURE 5.  Other genetic alterations in p16-RB pathway in 
NSCLC cell lines. The percentages of cell lines containing RB 
mutations, CCND1, CDK4, and CDK6 copy number gains are 
plotted. Copy numbers >3 are considered as copy number 
gains. NSCLC, non–small-cell lung carcinoma.
FIGURE 4.  The association 
between p16 inactivation and 
EGFR, KRAS, STK11 mutations, 
and smoke exposure. The fre-
quency of p16 WT, HD, methyla-
tion, and point mutation cases in 
each mutation type or smoking 
exposure group are presented 
in the bar graphs for cell lines, 
tumors, or combined. *Indicates 
statistically significant value. (for 
cell lines, p = 0.025; for tumors, 
p = 0.025; for combined, p = 
0.003). HD, homozygous dele-
tion; WT, wild-type.
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exposure and other methods of p16 inactivation. Five stud-
ies that contained data on HDs and/or point mutations with 
smoking history, were selected. There were total 305 smok-
ers and 99 nonsmokers included in these studies. The Woolf’s 
test showed that the studies were homogeneous (df = 4; 
p = 0.2680), and hence a fixed-effects model rather than ran-
dom-effects model was applied. The meta-analysis did not 
identify any significant association between never smoking 
and any of the p16 inactivation mechanisms (Fig. 7), although 
it did reveal a positive trend of p16 HD among never smokers. 
The overall OR was 0.61 (p = 0.1068) with 95% confidence 
interval between 0.338 and 1.11. These results corroborated 
the findings of our study.
DISCUSSION
To achieve the goals of our study with confidence, 
we used multiple methodologies to study p16 inactivation 
and to confirm inactivation by RNA and protein expression. 
Reassuringly, the data from each of these methodologies gave 
concordant results, confirming the accuracy of our data and 
conclusions of this comprehensive study.
We found p16 inactivation in 75% of cell lines, mainly 
via HD (53%) or methylation (33%), and occasionally by 
point mutations (13%). Because the p16 gene forms a crucial 
component of the RB growth regulatory pathway, we investi-
gated genetic alterations of other components of the pathway. 
Only 5% of cell lines had RB mutations. We also analyzed 
the copy number changes in these cell lines. Low-level gains 
of cyclin D1, CDK4, and CDK6 were present in 20% to 25% 
of the cell lines whereas high-level amplifications were rare. 
Thus, p16 inactivation was the major perturbation of the RB 
pathway noted in NSCLC cell lines.
Recent studies have shown the association between p16 
promoter methylation and KRAS mutation in lung adenocar-
cinoma. However, the association between p16 inactivation 
mechanisms and other common genetic alterations in lung 
adenocarcinoma is much less understood or has never been 
explored. In this study, we demonstrated that p16 inactivation 
occurred at similar frequencies regardless of the mutational 
status of EGFR, KRAS, and STK11 in lung adenocarcinoma; 
however, the patterns of p16 inactivation were significantly 
different, depending on the mutational status of these genes. 
FIGURE 6.  Meta-analysis of smoke exposure and 
p16 promoter methylation. A random-effects model 
was applied because of the heterogeneity of the 
studies selected. The square and the connecting 
lines indicate the OR and its CIs. The area of each 
square is proportional to the sample size of the 
study in the meta-analysis. The overall OR was 1.99 
(p < 0.05) with 95% CI between 1.48 and 2.72. OR, 
odds ratio; CIs, confidence intervals.
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We also confirmed the link between KRAS mutation and p16 
promoter methylation, and showed that EGFR mutation and 
p16 methylation were mutually exclusive. The negative and 
positive associations of p16 promoter methylation with EGFR 
and KRAS mutation, respectively, and the similar frequencies 
of p16 inactivation in both groups indicated the differences in 
the evolvement of epigenetic p16 alterations in these groups; 
despite the differences, it is clear that inactivation of the p16 
gene is involved in the pathogenesis of both EGFR- and 
KRAS-mediated lung cancer.
More recently, STK11 has been identified as being fre-
quently mutated in lung adenocarcinoma and could play an 
important role in lung cancer differentiation and metasta-
sis.11,50 However, the relationship between STK11 mutation 
and p16 inactivation has never been investigated. Our results 
showed no significant correlations between STK11 and p16 
inactivation. Because STK11 is usually inactivated by HDs, 
its true incidence may be underestimated. As with HD of p16, 
we examined STK11 by multiple means (sequencing, RNA 
expression, copy number) and are confident that are figures 
are accurate or near accurate.
Multiple studies have examined the relationship 
between smoking and mechanisms of p16 inactivation, 
however, the results have been variable. A number of stud-
ies reported that p16 promoter methylation was significantly 
associated with smoking but this finding was not reproduced 
by others.21,31 The effect of smoke exposure on p16 inactiva-
tion can be clarified by performing a meta-analysis. A recent 
study from China reported that smoking is positively corre-
lated with p16 hypermethylation in NSCLC.51 However, the 
meta-analysis in that study was limited to promoter methyla-
tion, which is not the most frequent mechanism of inactiva-
tion for p16. Our meta-analysis confirmed that smoking had 
a modest effect on p16 methylation. However when we per-
formed a second meta-analysis to include all three mecha-
nisms of p16 inactivation in smokers, we did not identify any 
significant association between never smoking and any spe-
cific p16 inactivation mechanism.
In conclusion, our results demonstrate that p16 inactiva-
tion occurs at similar frequencies regardless of the mutation 
status of EGFR, KRAS, and STK11 in lung adenocarcinoma. 
However, the patterns of inactivation mechanism differ sig-
nificantly depending upon the genetic mutation present. We 
also confirm that p16 methylation is linked to KRAS mutation 
and is mutually exclusive with EGFR mutation. Our results 
indicate that these genes are involved in different pathways 
and play different roles in development of lung adenocarci-
noma. Furthermore, our meta-analyses confirm the modest 
correlation between p16 methylation and smoking, and the 
trend of higher frequencies of p16 HD among never smok-
ers. These findings support the concept that tumors arising in 
never smokers are driven by distinct molecular mechanisms in 
lung tumorigenesis.6 Future studies are needed to explore the 
associations between specific p16 inactivation mechanisms 
and other environmental and genetic alterations to further 
elucidate the different molecular mechanisms involved in the 
development of lung adenocarcinoma.
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